Cell and Gene Outsourcing

  1. In Vivo CAR-T: Market Update And Manufacturing Implications For CDMOs 10/9/2026

    With CAR constructs largely validated, in vivo CAR-T now turns on delivery and manufacturability. Complexity moves from patient cells to vectors, nucleic acids, formulation, and analytics, reshaping sponsor expectations.

  2. Solvent Recovery Systems For Sustainable Pharma Manufacturing 10/9/2026

    Solvent recovery can reduce waste, but scaling it brings technical and regulatory risks. See how three approaches performed and what it takes to move from bench to commercial scale.

  3. Lonza Capabilities Update September 2026: Viral Vectors 10/8/2026

    Bingnan Gu, Head of Viral Vector R&D, shares how the company is helping developers turn complex in vivo LVV designs into clinical-ready products, and see the new analytics that reveal what’s really inside your vector.

  4. 4BaseBio Capabilities Update September 2026: Viral Vectors 10/8/2026

    Cell-free synthetic DNA templates can match or exceed plasmid-derived AAV titers while using less DNA, and they remove backbone sequences that plasmid-based production can package into the capsid.

  5. Recipharm Advanced Bio Capabilities Update September 2026: mRNA 10/8/2026

    RNA therapeutics are reshaping disease treatment, but success requires coordinated expertise in plasmid production, RNA synthesis, formulation, analytics, and manufacturing.

  6. Developing Custom GMP Lipids: A Patient-Driven Partnership 10/8/2026

    Custom lipid programs depend on how process development and manufacturing teams collaborate, from first design through scale-up to GMP production for LNP-based therapies.

  7. Pure Synthetic oDNA For mRNA Therapies 10/8/2026

    What changes when linearized plasmid DNA is replaced with a synthetic, cell-free template for IVT? Compare performance head to head, from enzyme kinetics to a CEPI-funded vaccine program.

  8. SKyvec™ Lenti For In Vivo Applications 10/7/2026

    When lentiviral vector moves from ex vivo intermediate to in vivo final drug product, purity, potency, and consistency expectations rise, and downstream capture performance becomes a central constraint.

  9. Simplifying Adenoviral Purification For Scalable Manufacturing 10/7/2026

    As vector design advances, downstream purification limits adenoviral manufacturing. A membrane-integrated hybrid train reduces product loss and process complexity at scale.

  10. Crude Peptide Purification Optimization For Scalable Manufacturing 10/7/2026

    Transitioning lentiviral vectors to final drug product raises quality demands. A simplified membrane-based capture step minimizes downstream losses that can constrain systemic dosing.